FDA Drug Trials Snapshots Updated with Eight 2025 NME and Biologic Approvals

Demographic transparency in clinical trial data is now a documented regulatory expectation, and the FDA's Drug Trials Snapshots program has added eight new entries covering approvals across oncology, cardiology, infectious disease, and rare disease through late 2025. For regulatory affairs leads and QA directors, the update signals continued agency focus on subgroup representation as a submission-readiness criterion, not a post-approval consideration.

The eight newly listed approvals span a range of therapeutic areas and molecular modalities. Oncology entries include imlunestrant (Inluriyо), approved 9/25/2025 for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer; sevabertinib (Hyrnu) for HER2-mutant non-squamous NSCLC (11/19/2025); and ziftomenib (Komzifti) for NPM1-mutant acute myeloid leukemia (11/13/2025). Cardiovascular approvals include aficamten (Myqorzo) for obstructive hypertrophic cardiomyopathy (12/19/2025) and etripamil (Cardamyst) for paroxysmal supraventricular tachycardia (12/12/2025). Zoliflodacin (Nuzolvence), approved 12/12/2025, addresses uncomplicated urogenital gonorrhea, while elamipretide (Forzinity), approved 9/19/2025, targets Barth syndrome in patients weighing at least 30 kg. Depemokimab (Exdensu) rounds out the list for severe eosinophilic asthma (12/16/2025).

Each Snapshot is published within 30 days of approval and captures demographic participation data, sex, race, age, and ethnicity, from the pivotal trials at the time of approval. The program covers only NMEs and original biologics approved since 2015; Snapshots are not revised post-publication, making the data a fixed record of the trial population at the regulatory decision point. For teams preparing submissions, this reinforces the importance of prospective diversity planning in protocol design rather than retrospective justification.

The agency's 2025 Summary Report, available for download at the Snapshots portal, provides aggregate trend data across the full cohort of that year's approvals. Regulatory affairs teams benchmarking their own trial demographics against industry norms will find the report a practical reference, particularly as FDA guidance on diversity action plans continues to evolve under the broader clinical trial modernization agenda.

The measurable outcome to track: whether the 2025 cohort shows improved demographic representation relative to prior years' summary reports, a comparison the agency's own data now makes possible across five consecutive annual cycles.

Source: FDA Drug Approvals and Databases via FDA.gov RSS Feed, 24 June 2026.